Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

S'inscrire

LEGN Legend Biotech Corporation

32,49

-0,29 (-0,88%)

28 Déc 2024 - Fermé

Retardé de 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

12/02/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Daniel Tucci, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Tom Heyman

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Legend Biotech (NASDAQ:LEGN)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024

Plus de graphiques de la Bourse Legend Biotech

Legend Biotech (NASDAQ:LEGN)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024

Plus de graphiques de la Bourse Legend Biotech

Actualités Legend Biotech Corporation

Form 144 - Report of proposed sale of securities
Jeudi 26 Décembre 2024 ( il y a 2 jours) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Jeudi 26 Décembre 2024 ( il y a 2 jours) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Lundi 23 Décembre 2024 ( il y a 5 jours) • Edgar (US Regulatory)

Legend Biotech to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Jeudi 19 Décembre 2024 ( il y a 1 semaine) • GlobeNewswire Inc.

CARVYKTI® Significantly Improved Minimal Residual Disease Negativity Compared to Standard of Care for Patients with Relapsed or Refractory Multiple Myeloma
Mardi 10 Décembre 2024 ( il y a 3 semaines) • GlobeNewswire Inc.

Form 144 - Report of proposed sale of securities
Lundi 2 Décembre 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans
Jeudi 14 Novembre 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mardi 12 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Legend Biotech Reports Third Quarter 2024 Results and Recent Highlights
Mardi 12 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Legend Biotech to Host Investor Event During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition
Jeudi 7 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Mardi 5 Novembre 2024 ( il y a 2 mois) • Edgar (US Regulatory)

Legend Biotech to Unveil Minimal Residual Disease Data from Landmark CARTITUDE-4 Trial in Multiple Myeloma
Mardi 5 Novembre 2024 ( il y a 2 mois) • GlobeNewswire Inc.

Plus d'articles sur Legend Biotech Corporation

JP Morgan Chase

Cie de SaintGobain

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales